Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva
Catalyst Pharmaceuticals Announces Settlement Of FIRDAPSE Patent Litigation With Teva Pharmaceuticals; Teva Will Not Market Its Generic Version Of FIRDAPSE In The U.S. Any Earlier Than February 25, 2035, If Approved By The FDA
Express News | Catalyst Pharmaceuticals Inc - Penging Firdapse Patent Litigation Against Hetero and Lupin Ongoing
Express News | Catalyst Pharmaceuticals Announces Settlement of Firdapse® (Amifampridine) Patent Litigation With Teva Pharmaceuticals
Express News | Teva Pharmaceuticals USA's Ezetimibe And Simvastatin, Tablet, 10 Mg; 10 Mg, 10 Mg; 20 Mg, 10 Mg; 20 Mg Discontinued
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
Mangkawat : red day but its still stable
Jaguar8 OP Mangkawat : Nothing big news for me on this one unless it comes with a monetary award
Mangkawat Jaguar8 OP : how about $BioLine Rx (BLRX.US)$ bioline rx. any news ? drop and drop.
Jaguar8 OP Mangkawat : It made an offering days ago
Mangkawat Jaguar8 OP : but price look like on risk to be delist. still below $1 .
View more comments...